捆绑白丝jk震动捧娇喘视频_国产一级不卡黄色av_久爱视频2019午夜视频_2020国产特级黄色自拍_亚洲熟妇AV日韩熟妇AV_国产精品欧美天美传媒_水蜜桃亚洲成人无码_歐美在線視頻網_日韩在线成人毛片_人妻激情中文字幕

 

 

 

It is understood that oseltamivir phosphate is the core anti infection product introduced by Peking University's pharmaceutical strategy. It inhibits the mature influenza virus from leaving the host cell by acting on the influenza virus neuraminidase, so as to inhibit the spread of influenza virus in the body, play a role in preventing and treating influenza, and is recommended by many diagnostic and treatment guidelines at home and abroad for the prevention and treatment of influenza A and B in adults and children.

 

 

 

Data shows that in 2023, the sales of oseltamivir preparations in China's three major terminal markets and six major markets (detailed statistical scope at the end of this article) will exceed 8.8 billion yuan. The domestically listed oseltamivir preparations include granules, capsules, and dry suspensions, with sales of oseltamivir phosphate granules exceeding 5.8 billion yuan.

 

 

 

Phosphate oseltamivir dry suspension is a 2024 national medical insurance product (Class B), which can be used for the treatment of influenza A and B in adults and children over 2 weeks old, as well as for the prevention of influenza in children over 1 year old. It has significant clinical efficacy and good medication safety.

 

 

 

Public information shows that Peking University Pharmaceutical is mainly engaged in the research and development, production, and sales of chemical drug preparations, as well as pharmaceutical distribution and other businesses. The company's pharmaceutical manufacturing sector currently focuses on core areas such as anti infective, analgesic, psychiatric, and chronic disease products, with generic drugs being the main focus.

 

 

 

In the field of anti infection, the main products of Peking University Medicine include the imported products, clindamycin hydrochloride palmitate granules (suitable for various infectious diseases caused by gram-positive bacteria, such as tonsillitis, acute bronchitis, pneumonia, etc.), moxifloxacin hydrochloride injection (suitable for adults (≥ 18 years old) with upper and lower respiratory tract infections, such as acute bacterial sinusitis, acute episode of chronic bronchitis, community acquired pneumonia, non complex skin and skin tissue infections, etc.), meropenem for injection (suitable for adults and children with infections caused by a single or multiple bacteria sensitive to meropenem, such as pneumonia (including hospital acquired pneumonia sexual pneumonia, urinary tract infection, etc.).

 

 

 

The company is strategically positioned as a "generic pharmaceutical technology enterprise" and adheres to the development strategy of "heavy pharmaceutical industry". Currently, it mainly engages in the research and development, production, and sales of chemical drug preparations, as well as pharmaceutical circulation and other businesses. The company stated in its institutional research that it will strive to enrich its product pipeline through consistency evaluation, new drug research and development, product introduction, and other methods to ensure that the company can continue to maintain steady growth in performance. In the future, the company will also combine its own product characteristics to further promote investment in research and development, products, etc., and strive to cultivate and develop new quality productivity.

 

 

 

Financial data shows that Peking University Pharmaceutical's operating revenue for the first three quarters of 2024 was 1.534 billion yuan, a year-on-year decrease of 7.32%; The net profit attributable to the parent company was 130 million yuan, a year-on-year increase of 182.49%; The net profit attributable to shareholders was 130 million yuan, a year-on-year increase of 221.85%; Basic earnings per share of 0.22 yuan; The net cash flow generated from operating activities was 63.8529 million yuan, a year-on-year increase of 464.24%.